

10th October, 2024

BSE Limited
P.J. Towers, Dalal Street, Fort,
Mumbai- 400 001
BSE scrip code: 543635

National Stock Exchange of India Limited
Exchange Plaza, Bandra-Kurla Complex,
Bandra (East), Mumbai – 400 051
NSE symbol: PPLPHARMA

Sub: Intimation under Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('SEBI Listing Regulations')

Dear Sir / Madam,

Pursuant to Regulation 30 of the SEBI Listing Regulations, we hereby inform that assessment orders were received from the office of the Navi Mumbai Municipal Corporation, Local Body Tax ('L.B.T') Department ('Orders') at the registered office of the Company on 9th October, 2024, levying penalty aggregating to Rs. 27,000/- under Rule 48 of the Maharashtra Municipal Corporations (Local Body Tax) Rules, 2010 (Amendment) Rules, 2013 read with the Maharashtra Municipal Corporation Act in addition to the tax demand and interest thereon.

The Orders were passed in connection with erstwhile Hemmo Pharmaceuticals Private Limited ('Hemmo') which was acquired as a wholly-owned subsidiary in June, 2021 and which was amalgamated with the Company in August, 2022. The Orders pertain to a period prior to the acquisition of Hemmo and address non-filing / erroneous filing of annual returns under applicable rules of the L.B.T. Department.

The Company is currently assessing the aforesaid Orders and will take appropriate steps within the stipulated time frame. The said Orders does not have any material impact on financials, operation or other activities of the Company.

Kindly take the above on record.

Yours truly,
For **Piramal Pharma Limited**

Tanya Sanish
Company Secretary

Piramal Pharma Limited

CIN: L24297MH2020PLC338592

Registered Office: Gr. Flr. Piramal Ananta, Agastya Corporate Park, Opp Fire Brigade, Kamani Junction, LBS Marg, Kurla (West), Mumbai – 400070 India

T +91 22 3802 3000 / 4000; Email: shareholders.ppl@piramal.com

piramalpharma.com